These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36058083)

  • 1. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification.
    Baratta F; D'Erasmo L; Bini S; Pastori D; Angelico F; Del Ben M; Arca M; Di Costanzo A
    Atherosclerosis; 2022 Sep; 357():51-59. PubMed ID: 36058083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
    Santos RD; Valenti L; Romeo S
    Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?
    Stols-Gonçalves D; Hovingh GK; Nieuwdorp M; Holleboom AG
    Trends Endocrinol Metab; 2019 Dec; 30(12):891-902. PubMed ID: 31630897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
    Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
    Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases.
    Zhang D; Mi Z; Peng J; Yang T; Han Y; Zhai Y; Song C; Teng X; Sun W; Guo J; Bilonda KP
    J Cardiovasc Pharmacol; 2023 May; 81(5):327-335. PubMed ID: 36917556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease and cardiovascular disease.
    Hyogo H; Chayama K; Yamagishi S
    Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
    Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
    Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.
    Park JH; Koo BK; Kim W; Kim WH;
    Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
    Muzurović E; Mikhailidis DP; Mantzoros C
    Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.
    Fargion S; Porzio M; Fracanzani AL
    World J Gastroenterol; 2014 Oct; 20(37):13306-24. PubMed ID: 25309067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.
    Duell PB; Welty FK; Miller M; Chait A; Hammond G; Ahmad Z; Cohen DE; Horton JD; Pressman GS; Toth PP;
    Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):e168-e185. PubMed ID: 35418240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].
    Kim HS; Cho YK
    Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
    Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
    Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.
    Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A
    Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Alcoholic Fatty Liver Disease and Vascular Disease.
    Forlano R; Mullish BH; Nathwani R; Dhar A; Thursz MR; Manousou P
    Curr Vasc Pharmacol; 2021; 19(3):269-279. PubMed ID: 32188385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
    Cai J; Zhang XJ; Ji YX; Zhang P; She ZG; Li H
    Circ Res; 2020 Feb; 126(5):679-704. PubMed ID: 32105577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of nonalcoholic fatty liver fibrosis score in estimating atherosclerotic cardiovascular disease risk.
    Huang YC; Huang JC; Chien HH; Lin CI; Chuang YS; Cheng HY; Lin WT; Lin YY; Chuang HY; Ho CK; Wang CL; Dai CY
    Nutr Metab Cardiovasc Dis; 2023 Dec; 33(12):2479-2487. PubMed ID: 37788955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.